Asthma and COPD together affect around half a billion people and cause close to 4 million deaths a year, with 90% of the premature deaths occurring in low- and middle-income countries. Steroid inhalers, central to long-term asthma control, are available in only 40% of countries.
47 of these 171 lines are pressurised metered-dose inhalers and 30 are nasal sprays, both requiring fill capability separate from standard oral and sterile lines.
Range depth
23 formoterol and 16 fluticasone presentations.
6 tiotropium presentations.
30 aqueous nasal presentations.
24 montelukast presentations.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.